Deslarzes Jean-Christophe
Known title: DirectorCIK: 0002092745
Deslarzes Jean-Christophe's purchase track record
Deslarzes Jean-Christophe has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/3/2026 | CSTM | $41K | pending | pending | — |
| 5/1/2026 | CSTM | $41K | -13.2% | pending | — |
| 3/2/2026 | CSTM | $41K | +33.1% | +1.4% | +11.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CSTM | ▲ Buy | Open Market | 1,490 | $41K | 8/3/2026 | View on chart |
| CSTM | ▲ Buy | Open Market | 1,325 | $41K | 5/1/2026 | View on chart |
| CSTM | ▲ Buy | Open Market | 1,665 | $41K | 3/2/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Barclays initiates coverage on Constellium with Equal-Weight rating
Barclays has started covering Constellium with an Equal-Weight rating and a $28 price target. This new analyst view comes as the company prepares to report its third-quarter results on October 28, 2026. While some analysts suggest the stock could see further gains, the new target is below the current average analyst estimate of $33.67.
Barclays initiates coverage on Constellium with Equal-Weight rating. Barclays has started covering Constellium with an Equal-Weight rating and a $28 price target. This new analyst view comes as the company prepares to report its third-quarter results on October 28, 2026. While some analysts suggest the stock could see further gains, the new target is below the current average analyst estimate of $33.67.